

To: Hobson, John (Peyton) [REDACTED]; Hojvat, Sally A

From: Elizabeth Holmes  
Sent: Wed 10/16/2013 2:51:58 AM  
Importance: Normal  
Received: Wed 10/16/2013 2:51:00 AM  
Theranos Workflow Diagrams FDA Confidential.pdf

Dear Peyton,

We've tried to compile comprehensive and simple workflow diagrams in follow up to our emails and as discussed on our last call.

Let me know if they make sense and if there are any questions or ambiguities and we can iterate them for you prior to circulation.

With my very best regards,

Elizabeth

=====

**PRIVILEGED AND CONFIDENTIAL COMMUNICATION**

IMPORTANT – This electronic transmission, and any files transmitted with it are confidential and/or legally privileged information. This information is intended solely for the use of the individual or entity to which they are addressed. Any disclosure, retransmission, reproduction, dissemination or other use of the contents of this information by persons or entities other than the intended recipient is strictly prohibited. If you have received this email in error, please contact us immediately and delete all copies. Please note that any views or opinions presented in this email are solely those of the author and do not necessarily represent those of Theranos, Inc. Finally, before opening or using attachments the recipient should check this email and any attachments for the presence of viruses. Theranos, Inc. accepts no liability for any damage caused by any virus transmitted by this email. Our sole responsibility is limited to resupplying any affected attachments.

Theranos, Inc., 1601 S. California Avenue, Palo Alto, CA, 94304  
650-838-9292 [www.theranos.com](http://www.theranos.com)

=====



**Overview of Sample Processing Workflow  
Prepared for FDA:**

**Phase I and Phase II of  
Theranos Business Operations**



This presentation and its contents are Theranos proprietary and confidential.

Confidential


THPFM0000154269

Theranos PSC  
(Theranos site operated by  
Theranos CLIA lab)

# Phase I: Current



Theranos High-Complexity CLIA-Certified Lab in Palo Alto, CA



Theranos Confidential


theranos

Confidential

THPFM0000154270

Theranos PSC  
(Theranos site operated by  
Theranos CLIA lab)

# Phase II: Post-FDA Clearance



Theranos Confidential

theranos

Confidential

THPFM0000154271

# TSPU & TLAS Description

(The TSPU and TLAS are designed and manufactured by Therasnos with no third party involvement.)

The TSPU and TLAS are also only used by Therasnos and are not sold.)

## Therasnos Sample Processing Unit (TSPU)

Performs automated pre-analytic processing\*:

- Sample separation (into plasma)
- Reagent addition/preparatory steps and associated signal generation
- Transmits raw signals (e.g. pixels or photon counts) to TLAS\*\*
- Connected to and controlled by TLAS under the oversight of Therasnos CLIA laboratory personnel

\*No operator decision making or manual processing required

\*\*NB – r e s u l t s cannot be generated on the TSPU (and thus of course could never be transmitted from or displayed on the TSPU)

## Therasnos Laboratory Automation System (TLAS)

Performs automated analysis and post-analytic processing:

- Pathologist and CLIA lab personnel oversight of TSPU
- Result derivation:
  - Signal analyzed
  - Replicates analyzed
  - Outliers analyzed
  - Controls analyzed
  - Calibrators analyzed
  - Signal converted to concentration based on analysis
- Pathologist and CLIA lab personnel oversight of analysis, post-analytic processing, and results

Therasnos Confidential

theranos

Confidential

THPFM0000154272